Interventions of Interest:

  • crisaborole (Eucrisa®, Pfizer, Inc.)
  • dupilumab (Dupixent®, Sanofi and Regeneron, Inc.)

Atopic dermatitis (eczema) is a chronic/chronically-relapsing skin condition characterized by itching and dry skin. Atopic dermatitis is common. It affects 5-20% of children worldwide, and approximately 11% of children in the US. It is also estimated to affect around 3-7% of adults in the US. Management of atopic dermatitis can create burdens for the family, and the disorder can decrease quality of life. Itching, in particular, can disrupt sleep and lead to daytime sleepiness, irritability, and psychological stress, and cosmetically important lesions can lead to social stress and isolation.

ICER’s report analyzed evidence on the comparative effectiveness of dupilumab, and found the price well-aligned with added value for patients. The recommendations highlight coverage considerations and actions for all stakeholders to improve evidence, ensure appropriate access, and manage affordability.


Final Documents

Below you will find the final documents from the assessment review process:

For questions, contact info@icer.org.

View the Key Stakeholders List.

Public Comments on Draft Scoping DocumentDownload
Response to Public Comments on Draft Evidence ReportDownload
Final Evidence Report and Meeting SummaryDownload
Report-at-a-GlanceDownload

ICER’s Chief Medical Officer David Rind, MD, MSc stated:

“Our analyses showed that dupilumab offers important clinical benefit for patients with moderate-to-severe atopic dermatitis. Moreover, the drug was priced in a way that aligns well with the benefit it provides to patients. We hope our report and recommendations can be a starting point for conversations among patient groups, payers, clinicians, and manufacturers, especially related to potential challenges with affordability, to ensure that those patients who can benefit from treatment with dupilumab are able to access it.”